spironolactone has been researched along with natriuretic peptide, brain in 76 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (30.26) | 29.6817 |
| 2010's | 41 (53.95) | 24.3611 |
| 2020's | 12 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A | 1 |
| Kalra, PR; Sharma, R | 1 |
| Imaki, T; Naruse, M; Sato, A; Takagi, S; Takano, K; Tanabe, A; Tsuchiya, K | 1 |
| Ahn, S; Duprez, D; Galanti, L; Gurné, O; Ketelslegers, JM; Robert, A; Rousseau, MF; Van Mieghem, W | 1 |
| Bellorini, M; Desnos, M; Duboc, D; Funck, F; Guillard, N; Jourdain, P; Loiret, J; Thebault, B | 1 |
| Fujii, M; Hayashi, M; Ishii, C; Maeda, K; Matsumoto, T; Ohnishi, M; Takayama, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yamamoto, T | 1 |
| Deorsola, A; Feola, M; Ferrero, V; Menardi, E; Milanese, U; Ribichini, F; Uslenghi, E; Vado, A; Visconti, G | 1 |
| Akioka, K; Iwao, H; Izumi, Y; Kim, S; Matsumoto, R; Nakamura, Y; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M | 1 |
| Riggs, JM | 1 |
| Dong, Q; Han, YP; Li, SR; Li, XC; Liu, G; Liu, HB; Liu, KS; Wang, XP; Wang, Y; Xu, LF; Zhang, LP | 1 |
| Asselbergs, FW; Lok, D; Plokker, HW; Smilde, TD; van de Wal, RM; van Gilst, WH; van Veldhuisen, DJ; Voors, AA | 1 |
| Bradley, J; Meyerrose, GE; Power, S; Roongsritong, C; Simoni, J; Sutthiwan, P | 1 |
| Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S | 1 |
| Berry, C; De Vito, G; Fisher, C; Galloway, S; Hillis, WS; McMurray, J; Murphy, N; Murphy, NF; Sattar, N; Seed, A; Vallance, P | 1 |
| Allolio, B; Angermann, CE; Bauersachs, J; Ertl, G; Frantz, S; Güder, G; Störk, S; Weismann, D | 1 |
| Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Sato, Y; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Burnett, JC; Chen, HH; Frantz, RP; Hodge, DO; Karon, BL; Miller, WL; Owan, TE; Redfield, MM; Rodeheffer, RJ | 1 |
| Ikeda, T; Kanemitsu, H; Komeda, M; Marui, A; Nishina, T; Tsukashita, M; Wang, J; Yoshikawa, E | 1 |
| Cohen-Solal, A | 1 |
| Bonnevie, L; Chanudet, X; Chenilleau, MC; Delarbre, D; Fraboulet, R; Guiraudet, O; Héno, P; Lambert de Crémeur, G; Martin, AC; Pelletier, C; Schiano, P | 1 |
| Kaikita, K; Kojima, S; Kusuhara, K; Nagayoshi, Y; Nakayama, M; Nishijima, T; Ogawa, H; Sugiyama, S; Sumida, H; Ueno, H; Yamamuro, M; Yoshimura, M | 1 |
| Berger, R; Cleland, JG; Fahrleitner-Pammer, A; Freemantle, N; Fruhwald, F; Pacher, R; Shankar, A; Tavazzi, L | 1 |
| Balmain, S; Dargie, HJ; Lowe, GD; Ng, LL; Rumley, A; Squire, IB; Steedman, T; Weir, RA | 1 |
| Hayashi, T; Kimura, S; Kitada, K; Kitaura, Y; Kobayashi, K; Kurumazuka, D; Matsuda, H; Matsumoto, C; Matsumura, Y; Mori, T; Shirakawa, H | 1 |
| Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T | 1 |
| Braunwald, E; O'Donoghue, M | 1 |
| Hayashi, T; Hosoda, K; Matsuo, M; Miyazaki, A; Sakaguchi, H; Tsuda, E | 1 |
| Ahmadi, R; Berger, R; Huelsmann, M; Moertl, D; Pacher, R; Peter, S; Wagner, B; Yamuti, S | 1 |
| Feldman, AM; Greenberg, B; Konstam, MA; Mukherjee, R; Pitt, B; Solomon, HA; Udelson, JE | 1 |
| Atalay, C; Aykan, S; Dogan, N; Gundogdu, C; Keles, MS | 1 |
| Januzzi, JL; Lloyd-Jones, DM; Mueller, T; Rehman, S; van Kimmenade, RR | 1 |
| Ferrari, M; Figulla, HR; Goebel, B; Jung, C; Kiehntopf, M; Lauten, A; Rademacher, W; Schumm, J; Uth, O | 1 |
| Emdin, M; Fontana, M; Gabutti, A; Giannoni, A; Iervasi, A; Mammini, C; Passino, C; Poletti, R; Vergaro, G; Zyw, L | 1 |
| Hanawa, H; Kobayashi, D; Kuroda, T; Murakami, S; Nakano, M; Narita, I; Oda, M; Wada, Y | 1 |
| Brunner-La Rocca, HP; Burkard, T; Julius, B; Maeder, MT; Muzzarelli, S; Nietlispach, F; Pfisterer, ME; Rickli, H; Toggweiler, S | 1 |
| Azibani, F; Benard, L; Carrier, L; Chatziantoniou, C; Delcayre, C; Fazal, L; Launay, JM; Merval, R; Polidano, E; Samuel, JL; Schlossarek, S; Tournoux, F | 1 |
| Abe, Y; Inokuma, S; Ohara, I; Shuto, C; Shuto, H; Sukigara, M; Suzuki, H | 1 |
| Cowie, MR | 1 |
| Nielsen, SE; Parving, HH; Persson, F; Rossing, K; Rossing, P; Schalkwijk, CG; Schjoedt, KJ; Stehouwer, CD | 1 |
| Abbühl, H; Brunner-La Rocca, HP; Erne, P; Gutmann, M; Maeder, MT; Peter, M; Pfisterer, M; Rickenbacher, P; Rickli, H; Vuilliomenet, A | 1 |
| Brunner-La Rocca, HP; Erne, P; Estlinbaum, W; Kiencke, S; Maeder, M; Mayer, K; Muzzarelli, S; Neuhaus, M; Pfisterer, ME; Sanders-van Wijk, S; Tobler, D | 1 |
| Aghamohammadzadeh, R; Blair, C; Gillies, H; Leopold, JA; Loscalzo, J; Maron, BA; Opotowsky, AR; Waxman, AB | 1 |
| Richards, AM | 1 |
| Almeida, S; Bettencourt, P; Carvalho, H; Ferreira, JP; Marques, I; Santos, M | 2 |
| Albrecht-Küpper, B; Bärfacker, L; Delbeck, M; Eitner, F; Hartmann, E; Kolkhof, P; Kretschmer, A; Schäfer, S; Steinke, W | 1 |
| Overbeck, P | 1 |
| Anker, SD; Böhm, M; Filippatos, G; Gheorghiade, M; Kim, SY; Kimmeskamp-Kirschbaum, N; Krum, H; Køber, L; Maggioni, AP; Nowack, C; Pieper, A; Pitt, B; Ponikowski, P; Voors, AA; Zannad, F | 1 |
| Bettencourt, P; Carvalho, H; Ferreira, JP; Marques, I; Oliveira, JC; Santos, M | 1 |
| Maisel, AS; Wettersten, N | 1 |
| Benz, V; Blumrich, A; Brix, S; Foryst-Ludwig, A; Grune, J; Höft, B; Kintscher, U; Klopfleisch, R; Kolkhof, P; Salatzki, J | 1 |
| Ajioka, M; Kato, M; Kim, SY; Kolkhof, P; Myoishi, M; Nowack, C; Sato, N; Shiga, T; Yamada, T | 1 |
| Anker, SD; Böhm, M; Filippatos, G; Gheorghiade, M; Kim, SY; Kimmeskamp-Kirschbaum, N; Kolkhof, P; Krum, H; Køber, L; Maggioni, AP; Nowack, C; Palombo, G; Pieper, A; Pitt, B; Ponikowski, P; Voors, AA; Zannad, F | 1 |
| Asensio-López, MC; Caballero, L; Fernández-Del Palacio, MJ; Gimeno-Blanes, JR; Lax, A; Navarro-Peñalver, M; Pascual-Figal, DA; Pérez-Martínez, MT; Sánchez-Más, J | 1 |
| Anstrom, KJ; Braunwald, E; Butler, J; Felker, GM; Hernandez, AF; Kalogeropoulos, A; Konstam, MA; Redfield, MM; Shah, MR; Tang, WH | 1 |
| Ferreira, JP; Girerd, N; Rossignol, P; Zannad, F | 1 |
| Bramlage, P; Fay, R; Girerd, N; Ketelslegers, JM; Michel, JB; Olivier, A; Pitt, B; Rossignol, P; Vincent, J; Zannad, F | 1 |
| Anand, IS; Claggett, B; Desai, AS; Fleg, JL; Liu, J; O'Meara, E; Pfeffer, MA; Pitt, B; Rector, TS; Shah, AM; Shah, SJ; Solomon, SD | 1 |
| Anstrom, KJ; Braunwald, E; Butler, J; Desvigne-Nickens, P; Felker, GM; Givertz, MM; Hernandez, AF; Kalogeropoulos, AP; Konstam, MA; Mann, DL; Margulies, KB; McNulty, SE; Mentz, RJ; Redfield, MM; Shah, M; Tang, WHW; Whellan, DJ | 1 |
| de Sa, EL; Duarte, K; Ferreira, JP; Flather, M; Hamm, CW; Montalescot, G; Orri, M; Pitt, B; Rossignol, P; Shi, H; Turgonyi, E; Verheugt, F; Vincent, J; Zannad, F | 1 |
| Bach, D; Bachran, D; Delles, C; Díez, J; Dominiczak, AF; Edelmann, F; González, A; Hasenfuss, G; López, B; Pieske, B; Ravassa, S; Trippel, T; Wachter, R | 1 |
| Dankowski, R; Karolko, B; Kobusiak-Prokopowicz, M; Kosmala, W; Kotwica, T; Mysiak, A; Przewłocka-Kosmala, M; Sacharczuk, W; Szyszka, A | 1 |
| Feng, P; Huang, W; Li, Z; Shi, W; Wang, SY; Wen, L; Xiang, R; Xiang, Y; Yang, Y | 1 |
| Chen, X; Shen, W; Wu, Q; Wu, T; Xu, G; Xu, X; Yang, P; Zhu, D | 1 |
| Ahmed, FZ; Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, JJ; Ferreira, JP; Girerd, N; González, A; Heymans, S; Latini, R; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Staessen, JA; Verdonschot, J; Zannad, F | 1 |
| Anand, IS; Claggett, BL; de Denus, S; Desai, AS; Jarolim, P; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Solomon, SD; Vaduganathan, M | 1 |
| Baron Toaldo, M; Borgarelli, M; Bussadori, C; Chiavegato, D; Ciaramella, P; Crosara, S; D'Agnolo, G; Dall'Aglio, E; Di Marcello, M; Dirven, M; Farina, F; Ferasin, L; Garelli-Paar, C; Guglielmini, C; Guillot, E; Lamb, K; Locatelli, C; Migliorini, F; Oliveira, P; Patteson, M; Piantedosi, D; Poggi, M; Porciello, F; Quintavalla, C; Santilli, RA; Savarino, P; Silva, J; Smets, P; Smith, S; Toschi Corneliani, R; Vannini, S; Zani, A | 1 |
| Brophy, TJ; DeVore, AD; Fonarow, GC; Fudim, M; Hammill, BG; Hernandez, AF; Kelly, JP; Peterson, ED; Pitt, B; Yancy, C | 1 |
| Imamura, T; Kinugawa, K; Tanaka, S; Ueno, H | 1 |
| Fang, L; Fang, Q; Fei, Y; Guo, X; Huang, Y; Liu, H; Wang, Q; Wu, C; Zhang, S | 1 |
| Ahmed, FZ; Brunner-La-Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, J; Díez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Grojean, S; Hazebroek, M; Heymans, S; Khan, J; Latini, R; Mamas, MA; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Pieske, B; Pizard, A; Rossignol, P; Rouet, P; Staessen, JA; Verdonschot, J; Wang, P; Zannad, F | 1 |
| Jiming, L; Tao, P; Zhitao, T | 1 |
| Hu, DX; Lian, JF; Lou, YM; Shao, GF; Shen, WJ; Xie, LY; Zheng, ZL; Zhou, JQ | 1 |
| Bozec, E; Clark, AL; Cleland, JG; Collier, T; Cosmi, F; Cuthbert, J; Díez, J; Edelman, F; Ferreira, JP; Girerd, N; González, A; Hazebroek, M; Heymans, S; Mariottoni, B; Pellicori, P; Petutschnigg, J; Pieske, B; Rossignol, P; Staessen, JA; Verdonschot, JAJ; Zannad, F | 1 |
| Ageev, FT; Ovchinnikov, AG | 1 |
| Dizaye, KF; Z Rashid, B | 1 |
5 review(s) available for spironolactone and natriuretic peptide, brain
| Article | Year |
|---|---|
New therapies for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Spironolactone; Treatment Outcome; United States | 2004 |
Natriuretic peptides in heart failure: should therapy be guided by BNP levels?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Prognosis; Risk Assessment; Risk Factors; Spironolactone | 2010 |
Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Calcitonin; Comorbidity; Diagnosis, Differential; Diuretics; Dyspnea; Female; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Natriuretic Peptide, Brain; Patient Discharge; Pneumonia, Bacterial; Prognosis; Severity of Illness Index; Spironolactone; Survival Analysis; Troponin | 2016 |
Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials.
Topics: Heart Failure; Hospitalization; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Procollagen; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone; Stroke Volume; Walking Speed | 2019 |
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Topics: Eplerenone; Heart Failure; Hospitalization; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Peptide, Brain; Network Meta-Analysis; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency; Spironolactone; Treatment Outcome | 2019 |
33 trial(s) available for spironolactone and natriuretic peptide, brain
| Article | Year |
|---|---|
Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.
Topics: Aged; Aldosterone; Cardiac Volume; Endomyocardial Fibrosis; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Procollagen; Prospective Studies; Spironolactone; Stroke Volume; Ventricular Function, Left; Ventricular Remodeling | 2001 |
Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Topics: Aged; Aged, 80 and over; Angiotensin II; Atrial Natriuretic Factor; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironolactone; Treatment Outcome | 2002 |
Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure.
Topics: Aged; Antihypertensive Agents; Cardiotonic Agents; Diuretics; Echocardiography; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironolactone; Ventricular Function, Left | 2003 |
[Effect of spironolactone on left ventricular remodeling in patients with acute myocardial infarction].
Topics: Female; Humans; Male; Myocardial Infarction; Myocardial Revascularization; Natriuretic Peptide, Brain; Peptide Fragments; Procollagen; Spironolactone; Ventricular Remodeling | 2005 |
Spironolactone improves diastolic function in the elderly.
Topics: Aged; Aged, 80 and over; Blood Pressure; Coronary Artery Disease; Diastole; Double-Blind Method; Female; Fibrosis; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardium; Natriuretic Peptide, Brain; Peptide Fragments; Procollagen; Prospective Studies; Spironolactone; Time Factors; Treatment Outcome | 2005 |
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Echocardiography; Female; Heart Ventricles; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironolactone; Tetrazoles; Ventricular Remodeling | 2006 |
Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Quality of Life; Receptors, Mineralocorticoid; Severity of Illness Index; Sickness Impact Profile; Spironolactone; Stroke Volume | 2007 |
Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Drug Synergism; Echocardiography; Female; Heart; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Spironolactone; Sympathetic Nervous System; Tetrazoles; Ventricular Function, Left; Ventricular Remodeling | 2007 |
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction.
Topics: Aged; Algorithms; Blood Urea Nitrogen; Creatinine; Cyclic GMP; Diuresis; Drug Administration Schedule; Drug Therapy, Combination; Endothelium; Female; Heart Failure; Humans; Kidney; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Agents; Natriuretic Peptide, Brain; Renal Insufficiency, Chronic; Spironolactone; Stroke Volume; Time Factors | 2008 |
Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Biomarkers; Cardiac Pacing, Artificial; Diuretics; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction.
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Male; Matrix Metalloproteinases; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Natriuretic Peptide, Brain; Predictive Value of Tests; Spironolactone; Stroke Volume; Tissue Plasminogen Activator; Ventricular Remodeling; von Willebrand Factor | 2010 |
N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Austria; Cardiology; Diuretics; Female; Furosemide; Heart Failure; Home Care Services, Hospital-Based; Humans; Length of Stay; Male; Natriuretic Peptide, Brain; Office Visits; Patient Readmission; Peptide Fragments; Pilot Projects; Primary Health Care; Prospective Studies; Referral and Consultation; Risk Assessment; Specialties, Nursing; Spironolactone | 2010 |
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Topics: Aged; Cohort Studies; Double-Blind Method; Eplerenone; Female; Gated Blood-Pool Imaging; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Procollagen; Quality of Life; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2010 |
Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
Topics: Aged; Biomarkers; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Hyperkalemia; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Odds Ratio; Potassium; Predictive Value of Tests; Prevalence; Prognosis; Prospective Studies; Risk Factors; Spironolactone; Survival Rate; Treatment Outcome | 2012 |
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease.
Topics: Albuminuria; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Endothelium; Female; Humans; Inflammation; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Spironolactone | 2013 |
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Disease Management; Diuretics; Female; Heart Failure; Hospitalization; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Stroke Volume; Treatment Outcome | 2013 |
Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Dose-Response Relationship, Drug; Drug Therapy; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Treatment Outcome | 2013 |
Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Diuretics; Double-Blind Method; Drug Therapy, Combination; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Phenylpropionates; Pilot Projects; Pyridazines; Severity of Illness Index; Spironolactone; Treatment Outcome; Young Adult | 2013 |
Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Disease Progression; Diuretics; Edema; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Potassium; Pulmonary Edema; Renal Insufficiency; Single-Blind Method; Spironolactone; Treatment Outcome | 2014 |
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Agents; Natriuretic Peptide, Brain; Peptide Fragments; Renal Insufficiency, Chronic; Spironolactone | 2015 |
Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Body Weight; Creatinine; Diuretics; Female; Heart Failure; Humans; Male; Matrix Metalloproteinase 2; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Spironolactone; Urea | 2015 |
A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
Topics: Adult; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Hyperkalemia; Japan; Naphthyridines; Natriuretic Peptide, Brain; Patient Safety; Peptide Fragments; Renal Insufficiency, Chronic; Spironolactone | 2016 |
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
Topics: Aged; Chronic Disease; Diabetes Mellitus; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Renal Insufficiency, Chronic; Spironolactone | 2016 |
Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
Topics: Acute Disease; Cause of Death; Disease Progression; Double-Blind Method; Dyspnea; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Mortality; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Treatment Outcome | 2016 |
Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac
Topics: Aged; Biomarkers; Endothelin-1; Eplerenone; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Natriuretic Peptide, Brain; Predictive Value of Tests; Spironolactone; Survival Rate; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2017 |
Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
Topics: Acute Disease; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Mortality; Natriuretic Peptide, Brain; Peptide Fragments; Spironolactone; Stroke Volume | 2017 |
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
Topics: Aged; Biomarkers; Double-Blind Method; Eplerenone; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Principal Component Analysis; Procollagen; Proportional Hazards Models; Spironolactone; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome; Troponin I; Troponin T | 2018 |
Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Topics: Aged; Biomarkers; Cardiomyopathies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrosis; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Natriuretic Peptide, Brain; Peptide Fragments; Phenotype; Prospective Studies; Spironolactone; Stroke Volume | 2018 |
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO
Topics: Aged; Aging; Biomarkers; Diabetes Mellitus, Type 2; Female; Fibrosis; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Spironolactone; Stroke Volume; Ventricular Function, Left | 2020 |
Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Biomarkers; Cardiovascular System; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironolactone; Stroke Volume | 2020 |
DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Dog Diseases; Dogs; Echocardiography; Female; Heart Valve Diseases; Male; Mitral Valve; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Spironolactone; Troponin I | 2020 |
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
Topics: Aged; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Proteomics; Spironolactone | 2021 |
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
Topics: Biomarkers; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironolactone; Stroke Volume; Tissue Plasminogen Activator; Ventricular Function, Left | 2022 |
38 other study(ies) available for spironolactone and natriuretic peptide, brain
| Article | Year |
|---|---|
Absolute, not relative, changes are important when interpreting trial data.
Topics: Clinical Trials as Topic; Heart Failure; Humans; Natriuretic Peptide, Brain; Spironolactone; Ventricular Function, Left; Ventricular Remodeling | 2001 |
Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; Corticosterone; Dexamethasone; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypertension; Imidazoles; Male; Natriuretic Peptide, Brain; Prodrugs; Pyridines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Spironolactone; Stroke; Tetrazoles; Time Factors | 2002 |
Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Follow-Up Studies; France; Furosemide; Heart Failure; Humans; Incidence; Lisinopril; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Severity of Illness Index; Spironolactone; Stroke Volume; Treatment Outcome | 2003 |
Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patients; Spironolactone | 2003 |
Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction.
Topics: Animals; Atrial Natriuretic Factor; Benzimidazoles; Biphenyl Compounds; Collagen Type I; Collagen Type III; Drug Synergism; Echocardiography; Gene Expression Profiling; Heart; Male; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; NF-kappa B; Rats; Rats, Wistar; Receptors, Angiotensin; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Tetrazoles; Transcription Factor AP-1; Ventricular Function, Left; Ventricular Remodeling | 2004 |
High prevalence of microalbuminuria in chronic heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biomarkers; Chronic Disease; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Netherlands; Peptide Fragments; Prevalence; Renin; Research Design; Spironolactone; Treatment Outcome | 2005 |
Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.
Topics: Aged; Aged, 80 and over; Aldosterone; C-Reactive Protein; Cause of Death; Cohort Studies; Comorbidity; Discriminant Analysis; Female; Follow-Up Studies; Heart Failure; Humans; Hydrocortisone; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Proportional Hazards Models; Prospective Studies; Receptors, Mineralocorticoid; Risk; Spironolactone | 2007 |
Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery.
Topics: Animals; Heart Aneurysm; Heart Ventricles; Hemodynamics; Lung; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Organ Size; Rats; Rats, Sprague-Dawley; Secondary Prevention; Spironolactone; Transforming Growth Factor beta1; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Hospital management of heart failure: improvement but still room for improvement at discharge...
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Diet; Diuretics; Drug Utilization; France; Heart Failure; Hospital Mortality; Hospitalization; Hospitals, Military; Humans; Life Style; Natriuretic Peptide, Brain; Patient Education as Topic; Patient Readmission; Peptide Fragments; Quality Assurance, Health Care; Spironolactone | 2008 |
Evaluation of heart failure management in a Military Hospital.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Diet; Diuretics; Drug Utilization; Follow-Up Studies; France; Heart Failure; Hospital Mortality; Hospitalization; Hospitals, Military; Humans; Life Style; Medical Audit; Natriuretic Peptide, Brain; Patient Education as Topic; Patient Readmission; Peptide Fragments; Quality Assurance, Health Care; Retrospective Studies; Spironolactone | 2008 |
Clinical factors affecting serum potassium concentration in cardio-renal decompensation syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Child; Disease Progression; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hyperkalemia; Male; Middle Aged; Natriuretic Peptide, Brain; Potassium; Regression Analysis; Renal Insufficiency; Renin-Angiotensin System; Severity of Illness Index; Spironolactone; Young Adult | 2010 |
Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Body Weight; Cell Size; Contraindications; Diet, Sodium-Restricted; Endomyocardial Fibrosis; Heart; Heart Failure; Hemodynamics; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Myocytes, Cardiac; Natriuretic Peptide, Brain; Organ Size; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Transforming Growth Factor beta; Tyrosine; Ventricular Remodeling | 2009 |
Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress.
Topics: Adrenocorticotropic Hormone; Aldosterone; Biomarkers; Chronic Disease; Diuretics; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hydrocortisone; Kaplan-Meier Estimate; Linear Models; Lipoproteins, LDL; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Oxidative Stress; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Spironolactone; Time Factors; Treatment Outcome | 2009 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Furosemide; Heart Failure; Hemodynamics; Humans; Natriuretic Peptide, Brain; Propanolamines; Recurrence; Spironolactone; Vasodilator Agents; Ventricular Dysfunction, Left | 2010 |
The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats.
Topics: Acute Lung Injury; Animals; Blood Gas Analysis; Disease Models, Animal; Lung; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Oxygen; Rats; Rats, Sprague-Dawley; Respiratory Distress Syndrome; Spironolactone; Surface-Active Agents; Treatment Outcome | 2010 |
Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients.
Topics: Acute Disease; Biomarkers; Cohort Studies; Diuretics; Dyspnea; Female; Humans; Interleukin-1 Receptor-Like 1 Protein; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Proportional Hazards Models; Receptors, Cell Surface; Receptors, Interleukin-1; Risk Assessment; Risk Factors; ROC Curve; Smoking; Spironolactone | 2010 |
Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Endothelin-1; Female; Heart Failure; Hemodynamics; Humans; Male; Microcirculation; Myocardial Perfusion Imaging; Natriuretic Peptide, Brain; Norepinephrine; Prognosis; Regional Blood Flow; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Statistics, Nonparametric; Stroke Volume; Ventricular Function, Left | 2011 |
Prognostic value of plasma renin activity in heart failure.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Death, Sudden; Defibrillators, Implantable; Diuretics; Electric Countershock; Female; Follow-Up Studies; Heart Failure; Humans; Male; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Norepinephrine; Peptide Fragments; Potassium; Prognosis; Proportional Hazards Models; Prospective Studies; Renin; ROC Curve; Sensitivity and Specificity; Sodium; Spironolactone; Stroke Volume | 2011 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazoles; Biphenyl Compounds; Carbazoles; Carvedilol; Drug Therapy, Combination; Dyspnea; Etanercept; Female; Furosemide; Glucocorticoids; Hand; Heart Failure; Humans; Immunoglobulin G; Lung Diseases, Interstitial; Natriuretic Peptide, Brain; Propanolamines; Radiography; Receptors, Tumor Necrosis Factor; Rheumatoid Factor; Ribonucleosides; Scleroderma, Systemic; Spironolactone; Sulfasalazine; Tetrazoles; Treatment Outcome | 2011 |
Aldosterone inhibits antifibrotic factors in mouse hypertensive heart.
Topics: Aldosterone; Animals; Animals, Newborn; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blood Pressure; Blotting, Western; Bone Morphogenetic Protein 4; Cells, Cultured; Cytochrome P-450 CYP11B2; Eplerenone; Female; Fibrosis; Galectin 3; Gene Expression; Hyperaldosteronism; Hypertension; Male; Mice; Mice, Transgenic; Mineralocorticoid Receptor Antagonists; Myocardium; Natriuretic Peptide, Brain; Organ Size; Renin; Reverse Transcriptase Polymerase Chain Reaction; Spironolactone | 2012 |
Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Eplerenone; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Spironolactone | 2012 |
Recent developments in the management of heart failure.
Topics: Algorithms; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Eplerenone; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Patient Care Team; Peptide Fragments; Spironolactone; Ventricular Dysfunction, Left | 2012 |
Brain natriuretic peptide-guided management of chronic heart failure: first do no harm.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone | 2013 |
Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Diuretics; Dose-Response Relationship, Drug; Female; Furosemide; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies; Spironolactone; Time Factors; Treatment Outcome | 2013 |
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Topics: Animals; Autoradiography; Cardiomegaly; Disease Models, Animal; Eplerenone; Heart Failure; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Peptide, Brain; Peptide Fragments; Rats; Rats, Sprague-Dawley; Rats, Wistar; Spironolactone; Tissue Distribution | 2014 |
[TOPCAT study. Heart failure: spironolactone disappoints in the "problem patient"].
Topics: Diuretics; Heart Failure; Humans; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Peptide Fragments; Randomized Controlled Trials as Topic; Research Design; Spironolactone; Treatment Failure | 2013 |
Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Eplerenone; Gene Expression; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Peptide, Brain; Spironolactone; Troponin T; Ventricular Remodeling | 2016 |
The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction.
Topics: Actinin; Animals; Atrial Natriuretic Factor; Blotting, Western; Eplerenone; Fibrosis; Gene Expression Regulation, Developmental; Heart; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Myosin Heavy Chains; Natriuretic Peptide, Brain; Rats; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; T-Box Domain Proteins; Ventricular Remodeling | 2016 |
A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironolactone | 2016 |
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Heart Arrest; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Randomized Controlled Trials as Topic; Spironolactone; Stroke Volume | 2017 |
Determinants of the beneficial effect of mineralocorticoid receptor antagonism on exercise capacity in heart failure with reduced ejection fraction.
Topics: Aged; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironolactone; Stroke Volume | 2018 |
Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Practice Patterns, Physicians'; Spironolactone; Stroke Volume | 2020 |
MitraClip or Ventricular Assist Device?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization Therapy; Carvedilol; Clinical Decision-Making; Disease Progression; Enalapril; Female; Heart Failure; Heart-Assist Devices; Hospitalization; Humans; Middle Aged; Mineralocorticoid Receptor Antagonists; Mitral Valve Annuloplasty; Mitral Valve Insufficiency; Natriuretic Peptide, Brain; Oxygen Consumption; Patient Selection; Pulmonary Wedge Pressure; Recurrence; Severity of Illness Index; Spironolactone; Treatment Outcome | 2020 |
Ventricular arrhythmia predicts poor outcome in polymyositis/dermatomyositis with myocardial involvement.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Autoantibodies; Cardiomyopathies; Dermatomyositis; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Mitochondria; Natriuretic Peptide, Brain; Peptide Fragments; Polymyositis; Prognosis; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Spironolactone; Survival Rate | 2021 |
A retrospective study on the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart failure.
Topics: Aged; Dose-Response Relationship, Drug; Echocardiography; Female; Heart Failure; Heart Function Tests; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Potassium; Retrospective Studies; Spironolactone; Walk Test | 2021 |
Effects of Spironolactone on Hypoxia-Inducible Factor-1α in the Patients Receiving Coronary Artery Bypass Grafting.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Biomarkers; Coronary Artery Bypass; Coronary Stenosis; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies; Risk Factors; Spironolactone; Time Factors; Treatment Outcome; Troponin I | 2021 |
[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].
Topics: Aminobutyrates; Amyloidosis; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Hypertrophy, Left Ventricular; Natriuretic Peptide, Brain; Phenotype; Spironolactone; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
The Impact of Procyanidin Extracted from Crataegus azarolus on Rats with Induced Heart Failure.
Topics: Animals; Biomarkers; Crataegus; Digoxin; Heart Failure; Male; Natriuretic Peptide, Brain; Peptide Fragments; Proanthocyanidins; Rats; Spironolactone | 2022 |